7/10/2019 | CV | Sunesis Pharmaceuticals to price an offering of series F convertible preferred stock
|
1/18/2019 | CV | New Issue: Sunesis Pharmaceuticals prices $8.5 million in series E convertible preferred stock
|
1/17/2019 | CV | Market Commentary: Aurora Cannabis convertibles offering eyed; Energizer flat; Ligand sees slight rebound
|
1/17/2019 | CV | Sunesis Pharmaceuticals offers series E convertible preferred stock
|
10/25/2017 | CV | New Issue: Sunesis Pharmaceuticals prices $2.5 million of convertible preferreds
|
10/24/2017 | CV | Sunesis Pharmaceuticals plans offering of convertible preferred stock
|
10/19/2016 | CV | New Issue: Sunesis Pharmaceuticals sells nearly $6 million of convertible preferred stock
|
10/18/2016 | CV | Sunesis Pharmaceuticals plans sale of convertible preferred stock
|
12/21/2015 | PP | Sunesis greenshoe exercised in $26.21 million stock, preferreds sale
|
12/16/2015 | PP | Sunesis prices $25 million public stock, convertible preferreds sale
|
3/12/2015 | PP | Sunesis could raise $30 million through at-the-market equity offering
|
2/27/2014 | PP | Sunesis prices $43.01 million public units offering at $9.25 per unit
|
2/26/2014 | PP | Sunesis Pharmaceuticals plans public offering of stock, warrants
|
4/10/2013 | PP | Sunesis could raise $30 million through at-the-market equity offering
|
10/19/2011 | PP | Sunesis Pharmaceuticals negotiates $25 million four-year loan facility
|
8/11/2011 | PP | Sunesis may raise $20 million through at-the-market equity offering
|
4/1/2009 | PP | New Issue: Sunesis orchestrates $43.5 million preferred units, stock sale
|
4/1/2009 | PP | Market Commentary: ATW settles C$4.78 million tranche; Fidelity secures $250 million; Hardy Oil to raise £10.8 million
|
11/16/2006 | BT | Sunesis at sector perform, $7 price target by RBC
|
11/15/2006 | BTCVHY | Sunesis files $75 million debt, stock shelf
|
11/10/2006 | BT | Jefferies starts Sunesis at buy
|
11/8/2006 | BT | RBC begins Sunesis at sector perform
|
11/2/2006 | BT | Sunesis' third-quarter revenues down at $1.9 million, R&D spending up
|
8/10/2006 | BT | Sunesis second-quarter revenues up at $6.7 million, enrollment in several clinical trials continues
|
7/11/2006 | BT | Sunesis says it will report data from phase 1 clinical trial SNS-595 for leukemia in September
|
6/12/2006 | BT | Sunesis gets $4.25 million milestone payment from Merck
|
6/6/2006 | BT | Sunesis reports SNS-595 shows activity against tumors, is well tolerated
|
4/7/2006 | BT | Sunesis, UCSF in research agreement to identify small molecule drug candidates
|
4/4/2006 | BT | Sunesis data of SNS-595 shows promising clinical activity
|
4/4/2006 | BT | Sunesis demonstrates SNS-032 benefits at cancer research meeting
|
3/24/2006 | BT | Sunesis says revenue increases, but not enough to prevent $5.3 million 4Q net loss
|
3/20/2006 | BT | Market Commentary: Boston Life Sciences' stock up as phase 3 trial ends early; BioMarin's stock dips on follow-on stock deal
|
3/20/2006 | BT | Sunesis starts phase 2 clinical trial of SNS-595 in small cell lung cancer
|
3/20/2006 | PP | Market Commentary: Vyyo prepares to close $25 million stock, note sale; Bodisen's stock advances 13% on stock offering
|
3/17/2006 | BT | Market Commentary: Sunesis stock leaps 11.4% on $45 million PIPE; Salix's stock drops on FDA approval of OsmoPrep
|
3/17/2006 | PP | Market Commentary: Energy Metals prices two PIPEs totaling C$44 million; Sunesis' stock jumps on word of $45 million PIPE
|
3/17/2006 | BTPP | New Issue: Sunesis to settle $45 million private placement of shares
|
2/15/2006 | BT | Sunesis issues 404,040 shares to Bristol-Myers
|
1/4/2006 | BT | Sunesis begins phase 2 study of lung cancer drug, pays Dainippon $500,000 milestone
|
12/7/2005 | BT | Sunesis gets $500,000 milestone payment from Biogen for cancer treatment collaboration
|
11/17/2005 | BT | Sunesis cancer drug SNS-595 stabilized 29% of patients in phase 1 study
|
11/15/2005 | BT | Sunesis starts phase 1 trial of SNS-595 for acute leukemia
|
9/30/2005 | BT | Market Commentary: Predix IPO price range emerges; Genomic, Avalon, Sunesis a mix; Progenics up; BioDelivery slides
|
9/29/2005 | BT | Market Commentary: Genomic, Avalon sink after IPOs price at low end; Forest, Cypress dive; SkinMedica's IPO on deck
|
9/28/2005 | BT | Market Commentary: Panacos, SkyePharma add to deal slate; Incyte, Endo drop on news; Electro-Optic rejigs talk, syndicate
|
9/27/2005 | BT | Market Commentary: Sunesis sinks after below-range IPO; Biogen, Elan bounce then retreat; Genentech sharply lower
|
9/27/2005 | BT | New Issue: Sunesis sells 6 million shares at $7 each, below range of $9 to $11
|
9/23/2005 | BT | Market Commentary: Nektar upsizes home-run convertible, Renovis raves, Acusphere sinks after follow-ons; Cyberonics slips
|
9/22/2005 | BT | Market Commentary: Nektar convertible at bat along with follow-ons from GTx, Renovis; Cyberonics prices wide, closes off
|
9/21/2005 | BT | Market Commentary: Nektar, Cyberonics pitch converts; QLT spirals; Chiron players shift to 2.75s; Alkermes stumbles
|
9/16/2005 | BT | Market Commentary: Meridian Biosciences slips in spot deal; Myogen, Geron deals show improved reception
|
9/7/2005 | BT | Market Commentary: ID Biomedical climbs 13% on Glaxo acquisition; Chiron still rising; Nektar zooms over 10%
|
9/6/2005 | BT | Market Commentary: Chiron rises on rejection of bid from Novartis; Barr, Teva gain; New River higher; Andrx falls
|
9/1/2005 | BT | Market Commentary: Chiron shares, convertibles gain on Novartis bid; Par Pharma up 1%; Cephalon up 5%, Abgenix up 9%
|
9/1/2005 | BT | Sunesis Pharmaceuticals opens IPO price talk at $9-$11 per share
|